First universal pharmacophore model for hERG1 K+ channel activators: acthER.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Molecular Graphics and Modelling

• Publication date

  2017-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jmgm.2017.03.020PMID 28499268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potassium channels in the heart: structure, function and regulation

  2017cited by this paper
• Structure of the voltage-gated K+ channel Eag1 reveals an alternative voltage sensing mechanism

  2016cited by this paper
• Multi-scale Modeling of the Cardiovascular System: Disease Development, Progression, and Clinical Intervention

  2016cited by this paper
• Potassium channels in the heart : structure , function and regulation

  2016cited by this paper
• Role of the pH in state-dependent blockade of hERG currents

  2016cited by this paper
• Allosteric Modulation of Kv11.1 (hERG) Channels Protects Against Drug-Induced Ventricular Arrhythmias

  2016cited by this paper
• In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia

  2015cited by this paper
• Synthesis and biological evaluation of negative allosteric modulators of the Kv11.1(hERG) channel.

  2015cited by this paper
• Kinetic model for NS1643 drug activation of WT and L529I variants of Kv11.1 (hERG1) potassium channel.

  2015cited by this paper
• Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4.

  2015cited by this paper
• NS1643 interacts around L529 of hERG to alter voltage sensor movement on the path to activation.

  2015cited by this paper
• Pharmacological and electrophysiological characterization of AZSMO‐23, an activator of the hERG K+ channel

  2015cited by this paper
• Structure Driven Design of Novel Human Ether-A-Go-Go-Related-Gene Channel (hERG1) Activators

  2014cited by this paper
• A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity.

  2014cited by this paper
• Rehabilitating drug-induced long-QT promoters: In-silico design of hERG-neutral cisapride analogues with retained pharmacological activity

  2014cited by this paper
• Structure-Guided Topographic Mapping and Mutagenesis to Elucidate Binding Sites for the Human Ether-a-Go-Go-Related Gene 1 Potassium Channel (KCNH2) Activator NS1643

  2012cited by this paper
• Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel

  2012cited by this paper
• Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding

  2012cited by this paper
• Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules

  2011cited by this paper
• Atomistic models for free energy evaluation of drug binding to membrane proteins.

  2011cited by this paper
• Combined Receptor and Ligand-Based Approach to the Universal Pharmacophore Model Development for Studies of Drug Blockade to the hERG1 Pore Domain

  2011cited by this paper
• Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs.

  2010cited by this paper
• Interactions of H562 in the S5 helix with T618 and S621 in the pore helix are important determinants of hERG1 potassium channel structure and function.

  2009cited by this paper
• PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance

  2009cited by this paper
• Electrophysiologic characterization of a novel hERG channel activator.

  2009cited by this paper
• 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic Acid (PD-307243) Causes Instantaneous Current through Human Ether-a-go-go-Related Gene Potassium Channels

  2008cited by this paper
• Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction.

  2008cited by this paper
• Probing the Binding Sites and Mechanisms of Action of Two Human Ether-a-go-go-Related Gene Channel Activators, 1,3-bis-(2-Hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243)

  2008cited by this paper
• Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator

  2007cited by this paper
• Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel Activator

  2006cited by this paper
• Activation of Human ether-a-go-go-Related Gene Potassium Channels by the Diphenylurea 1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643)

  2006cited by this paper
• Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

  2006cited by this paper
• Use of an Induced Fit Receptor Structure in Virtual Screening

  2006cited by this paper
• Mallotoxin Is a Novel Human Ether-a-go-go-Related Gene (hERG) Potassium Channel Activator

  2006cited by this paper
• PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results

  2006cited by this paper
• The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.

  2006cited by this paper
• Discovery of a Small Molecule Activator of the Human Ether-a-go-go-Related Gene (HERG) Cardiac K+ Channel

  2005cited by this paper
• Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

  2005cited by this paper
• Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

  2004cited by this paper
• Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG

  2003cited by this paper
• Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.

  2002cited by this paper
• HERG K+ channels: friend and foe.

  2001cited by this paper
• Ion channels and their functional role in vascular endothelium.

  2001cited by this paper
• Spectrum of Mutations in Long-QT Syndrome Genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2

  2000cited by this paper
• Ligand-gated ion channel interactions with cytoskeletal and signaling proteins.

  2000cited by this paper
• Structure and function of cardiac potassium channels.

  1999cited by this paper
• Development and validation of a genetic algorithm for flexible docking.

  1997cited by this paper
• Modulation of ion-channel fundion by G-protein-coupled receptors

  1994cited by this paper
• Hormonal Control of Ion Channel Gating

  1993cited by this paper
• Potassium channel activator drugs: Mechanism of action, pharmacological properties, and therapeutic potential

  1992cited by this paper
• A distinct potassium channel polypeptide encoded by the Drosophila eag locus

  1991cited by this paper

• hERG agonists pose challenges to web-based machine learning methods for prediction of drug-hERG channel interaction.

  2023cites this paper
• Otoprotection against aminoglycoside- and cisplatin-induced ototoxicity focusing on the upstream drug uptake pathway

  2023cites this paper
• Utilizing Heteroatom Types and Numbers from Extensive Ligand Libraries to Develop Novel hERG Blocker QSAR Models Using Machine Learning-Based Classifiers

  2023cites this paper
• Investigation of potential descriptors of chemical compounds on prevention of nephrotoxicity via QSAR approach

  2022cites this paper
• Molecular modeling in cardiovascular pharmacology: current state of the art and perspectives.

  2021cites this paper
• A pharmacological master key mechanism that unlocks the selectivity filter gate in K+ channels

  2019influential citation
• Open-Access Activity Prediction Tools for Natural Products. Case Study: hERG Blockers.

  2019cites this paper
• Structure/Activity Analysis of TASK-3 Channel Antagonists Based on a 5,6,7,8 tetrahydropyrido[4,3-d]pyrimidine

  2019cites this paper